Mark Lawrence Johnson is one of the early pioneers to develop policy and procurement in the European biodefense market for medical countermeasures (MedCM). He has accrued a mature and extensive network. His professional credibility was born over 20 years ago when he began to represent leading global pharmaceutical companies such as Merck & Co., Eli Lilly, and Astellas. Following response to the European Commission’s (EC) Green Paper on CBRN preparedness in 2007, his participation at EC CBRN taskforce meetings was instrumental in getting fundamental economic elements adopted in its corresponding recommendations and action plan. He holds an MBA from Wake Forest University and a BA in Business Management from the University of Maryland. He is currently a Doctoral candidate at the Paris 2 University, Panthéon-Assas (LEMMA) working to determine economic mechanisms for achieving international availability of CBRN MedCM Mark Lawrence Johnson is one of the early pioneers to develop policy and procurement in the European biodefense market for medical countermeasures (MedCM). He has accrued a mature and extensive network. His professional credibility was born over 20 years ago when he began to represent leading global pharmaceutical companies such as Merck & Co., Eli Lilly, and Astellas. Following response to the European Commission’s (EC) Green Paper on CBRN preparedness in 2007, his participation at EC CBRN taskforce meetings was instrumental in getting fundamental economic elements adopted in its corresponding recommendations and action plan. He holds an MBA from Wake Forest University and a BA in Business Management from the University of Maryland. He is currently a Doctoral candidate at the Paris 2 University, Panthéon-Assas (LEMMA) working to determine economic mechanisms for achieving international availability of CBRN MedCM

Vaccines & Vaccination